On Wednesday flagged promising late-stage demo results for its new Cagrilinitide obesity therapy, as being the Danish pharmaceutical large seeks a following-technology choice to its blockbuster Wegovy fat-decline drug. Having said that, Cagrilintide is still in Period II/III trials. Though the early info is fascinating, it hasn't yet been approved https://edmundo691zwp9.wikiexcerpt.com/user